Why is mifepristone not widely used by reproductive endocrinology and infertility specialists for EPL management?

Label:chem

Topic
Mifepristone is subject to the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which imposes strict regulations on its prescription and distribution. These restrictions include certification requirements for providers and pharmacies, as well as patient consent and follow-up protocols.
Answer
The primary reason for the limited use of mifepristone among reproductive endocrinology and infertility specialists is the difficulty in accessing the medication due to REMS program restrictions. Additionally, some providers may be unfamiliar with its use for EPL management.
Return to Home Chemical List
Knowledge you may be interested in
What is the role of mifepristone in the management of early pregnancy loss (EPL)? What is the role of mifepristone and misoprostol in the management of early pregnancy loss (EPL)? What is the role of mifepristone in cervical ripening and labor induction? What is the role of halenaquinone (HQ) in the treatment of leukemia, particularly in Molt 4 cells? What role does ropivacaine play in the treatment of nasopharyngeal carcinoma (NPC)? How do ropivacaine and lidocaine affect mitochondrial superoxide production in osteosarcoma cells? What is the impact of ropivacaine and lidocaine on mitochondrial morphology in osteosarcoma cells? How do ropivacaine and lidocaine affect alkaline phosphatase (ALP) activity in osteosarcoma cells? What are the effects of ropivacaine and lidocaine on apoptosis-related gene expression in osteosarcoma cells? How do ropivacaine and lidocaine affect cell proliferation in osteosarcoma? How does the combination of mifepristone and misoprostol compare to misoprostol alone in managing EPL? What are the barriers to the use of mifepristone for EPL management in assisted reproductive technology (ART) pregnancies? How does raloxifene function as an anticancer agent in breast cancer treatment? What is the role of cyclodextrins in enhancing the solubility and dissolution of raloxifene? How do pH-modifying excipients like tartaric acid and azelaic acid improve the solubility and dissolution of raloxifene? What is the impact of raloxifene-tartaric acid complexes on cytotoxicity in breast cancer cells? How does the cellular uptake of raloxifene complexes with tartaric acid and HP β-CD compare in Caco-2 cells? How do genetic variants in the ESR1 gene influence the treatment response to raloxifene in schizophrenia-spectrum disorders (SSD)? How do genetic variants in the COMT gene influence the treatment response to raloxifene in schizophrenia-spectrum disorders (SSD)? How do genetic variants in the UGT1A8 gene influence the treatment response to raloxifene in schizophrenia-spectrum disorders (SSD)?